Moderna to Pay About $1 Billion to Settle Arbutus Litigation (3)

Moderna Inc. agreed to pay $950 million to settle litigation related to the delivery technology behind its Covid shot, removing a looming financial risk for the struggling vaccine maker.

The company has settled all litigation worldwide with Arbutus Biopharma Corp. and Genevant Sciences GmbH over its existing and future vaccines, with no future royalties owed.

At issue were claims that Moderna had infringed on patents owned by Genevant and Arbutus related to lipid nanoparticles, or tiny bubbles of fat that Moderna used to deliver its Covid shot inside patients.

Moderna plans to argue that it has government-contractor immunity that limits ...